Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 2/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
| ▸ | MMP7 | P09237 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.47 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13841248 | 0.73 | ITGB1 (0.50) | ALDH1A1MEN1KMT2AITGB1ITGA4 | |
| SCHEMBL29416320 | 0.73 | ALDH1A1 (0.47) | NPC1RAB9AALDH1A1LMNAHSP90AA1 | |
| SCHEMBL19430104 | 0.73 | ELOVL1 (0.53) | NPC1RAB9AALDH1A1LMNAGAA | |
| SCHEMBL390057 | 0.72 | ABCG2 (0.80) | NPC1RAB9AALDH1A1LMNAHSP90AA1 | |
| SCHEMBL31324782 | 0.70 | FPR2 (0.61) | NPC1RAB9AMMP2MMP1MMP3 | |
| SCHEMBL387105 | 0.69 | SMN1; SMN2 (0.73) | NPC1RAB9AALDH1A1LMNAHSP90AA1 | |
| SCHEMBL19430034 | 0.69 | MAPT (0.52) | NPC1RAB9AALDH1A1LMNAGAA | |
| SCHEMBL390210 | 0.68 | CYP1A2 (1.00) | NPC1RAB9AALDH1A1LMNAHSP90AA1 | |
| SCHEMBL13309900 | 0.68 | ABCG2 (0.56) | NPC1RAB9ALMNAABCG2ABCB1 | |
| SCHEMBL15583227 | 0.68 | NPR3 (0.59) | ALDH1A1CYP1A2MMP2MMP9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803753-B2 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-20070072803-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072803-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | GLP1R, GPR119, GIPR | NPC1 964/4885RAB9A 1443/4885ALDH1A1 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.